All the news Showing 10 of 81 articles from: Protease inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... New Merck combination pill Zepatier approved for hepatitis C treatment in the United States Keith Alcorn / 01 February 2016 Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor) and elbasvir (an NS5A inhibitor) ... Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients Liz Highleyman / 19 November 2015 A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced genotype 1 hepatitis C patients with cirrhosis, without the need for ribavirin, according to study ... New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study Keith Alcorn / 16 November 2015 A combination of two experimental direct-acting antivirals developed by AbbVie cured 97 to 100% of people without cirrhosis with genotype 1 hepatitis C infection in a mid-stage phase 2 study presented this ... Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs Liz Highleyman / 16 November 2015 Merck's grazoprevir/elbasvir coformulation cured hepatitis C infection in 92% of injecting drug users receiving opioid substitution therapy in the C-EDGE CO-STAR study, according to a presentation on Sunday at the 2015 AASLD ... Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough Liz Highleyman / 13 May 2015 A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver ... Grazoprevir / elbasvir highly effective in previously untreated hepatitis C Keith Alcorn / 24 April 2015 A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with gentoypes 1, 4 or 6 hepatitis C infection, according to results of the C-EDGE trial, ... AbbVie next-generation hepatitis C drugs look promising in early studies Liz Highleyman / 03 March 2015 AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in people with genotype 1 chronic hepatitis C in a three-day monotherapy study, as well as potent and ... Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use Liz Highleyman / 09 December 2014 Regimens containing sofosbuvir (Sovaldi) – including sofosbuvir plus simeprevir (Olysio) – work well for people with hepatitis C genotype 1 in real-world use, which to date has included some of the patients most urgently ... AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection Liz Highleyman / 03 December 2014 AbbVie's 3D regimen (paritaprevir/ombitasvir/ritonavir plus dasabuvir) with ribavirin for 12 weeks and Gilead Science's sofosbuvir (Sovaldi) plus ribavirin for 24 weeks both produced good sustained virological response rates for most people with ... ← First12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive